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Mucositis is an acute inflammation of the oral mucosa because of radiotherapy and/or chemotherapy. All patients receiving
radiotherapy in the head and neck region develop oral mucositis. The aim of this study was to analyse the effects of selective oral flora
elimination on radiotherapy-induced oral mucositis, in a double-blind, randomised, placebo-controlled trial. Sixty-five patients with a
malignant tumour in the head and neck regions to be treated with primary curative or postoperative radiotherapy participated in this
study. The patients received either the active lozenges of 1g containing polymyxin E 2mg, tobramycin 1.8mg and amphotericin B
10mg (PTA) (33 patients) or the placebo lozenges (32 patients), four times daily during the full course of radiotherapy. Mucositis,
changes in the oral flora, quality of feeding and changes of total body weight were assessed. Mucositis score did not differ between
the groups during the first 5 weeks of radiotherapy. Nasogastric tube feeding was needed in six patients (19%) of the placebo group
and two patients (6%) of the PTA group (P¼0.08). Mean weight loss after 5 weeks of radiation was less in the PTA group (1.3kg)
(s.d.: 3.0) than in the placebo group (2.8kg) (s.d.: 2.9) (P¼0.05). Colonisation index of Candida species and Gram-negative bacilli was
reduced in the PTA group and not in the placebo group (Po0.05). No effect on other microorganisms was detected. In conclusion,
selective oral flora elimination in head and neck irradiation patients does not prevent the development of severe mucositis.
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Radiotherapy in head and neck cancer patients can induce oral
mucositis, which is an acute inflammation of the oral mucosa.
Until now no effective intervention has been developed to prevent
oral mucositis in radiotherapy (Sutherland and Browman, 2001).
This prevention is even more relevant now because altered
fractionation schedules for the treatment of head and neck
malignancies induce more severe mucositis (Kaanders et al,
1999). All patients receiving radiotherapy in the head and neck
region develop oral mucositis to some extent, depending on
radiation schedule, radiation field, radiation volume and cumula-
tive dose (Miralbell et al, 1999). Clinically, mucositis appears in a
conventional radiation scheme after a cumulative radiation dose of
10–20Gy as a white discoloration of the mucosa because of
hyperkeratinisation. The next stage is a deepening erythema
followed by the development of pseudomembranes and ulcera-
tions. Severe mucositis, appearing as pseudomembranes, will
develop at the end of the third week of radiation, after about 30Gy
(Baker, 1982; Spijkervet et al, 1989b). Prevention of severe
mucositis is important because mucositis affects the patient’s
feeding status, physical and mental well-being and it can influence
the course of radiotherapy (Sutherland and Browman, 2001).
Further oral pain because of mucositis has a serious impact on the
quality of life of patients (Miralbell et al, 1999).
Several mechanisms are supposed to play a role in the
development of mucositis: changes at the cellular level of the
basal cell layer, inflammatory process in the epithelium and
influence of bacteria on mucosal surface. Changed oral flora,
colonising the oral mucosa, may aggravate the mucosa reaction
because of radiation (Van Saene and Martin, 1990). The carriage
and colonisation of aerobic Gram-negative bacilli are thought to
play a role in the pathogenesis of irradiation mucositis (Bernhoft
and Skaug, 1985). A hypothesis has been proposed on the
development of mucositis in four consecutive phases, in which
the ulcerative/bacterial phase is thought to play a role in the
development of fibrous pseudomembranes of the oral mucosa
(Sonis, 1998). A pilot study in 15 patients reported the protective
effect of an antibiotic lozenge for selective elimination of the oral
flora (Spijkervet et al, 1990). Less severe mucositis and a less mean
mucositis score compared to a historical control group was
observed. None of the PTA-(polymyxin E 2mg, tobramycin 1.8mg
and amphotericin B 10mg) treated patients needed nasogastric
tube feeding. In a cohort study including 36 patients, it was found
that PTA lozenges may reduce irradiation mucositis (Kaanders
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let al, 1995). In contrast, randomised studies reported conflicting
effects on mucositis by selective oral flora elimination (Symonds
et al, 1996; Okuno et al, 1997; Wijers et al, 2001).
The aim of this study was to evaluate in a randomised, double-
blind, placebo-controlled trial the effects of selective oral flora
elimination on the development of irradiation-induced oral
mucositis, feeding, weight loss and colonisation of aerobic
Gram-negative bacilli and yeast.
PATIENTS AND METHODS
Protocol
Patients with a malignant tumour in the head and neck regions to
be treated with primary curative or postoperative radiotherapy
were eligible for this study. Inclusion criteria for the study were:
external bilateral irradiation via parallel-opposed portals by a
linear accelerator (4–6MeV), fractionation of 2Gy daily, five times
a week, with a prescribed dose of at least 50Gy and at least 50% of
the oral mucosa in the field of radiation. The dose specification
was in line with ICRU 50 recommendations (Anonymous, 1993).
Criteria for exclusion were: (1) an oral mucosa defect other than
related to tumour surgery; (2) need for an obturator or resection
prosthesis and; (3) treatment with antibiotics for an oral infection
the last 2 weeks before the start of irradiation.
As a standard procedure all patients were evaluated before
radiation treatment for potential risk factors for oral complications
by means of a thorough oral and dental evaluation, including a
radiographic examination. All potential risk factors were elimi-
nated appropriately before the start of radiotherapy. The
supportive oral care regimen consisted of a daily protocol of
cleansing the oral cavity by means of spraying with saline by the
dental hygienist, and mouth rinsing by the patients with a salt–
baking soda solution at least eight times a day to remove sticky
saliva and debris. Dentate patients applied a neutral fluoride gel
every second day with custom-made trays and edentulous patients
were not allowed to wear their dentures during the course of
radiotherapy (Jansma et al, 1992).
The Medical Ethical Committee approved the study and all
eligible patients gave written informed consent.
Assignment
The eligible patients were randomised to receive active lozenges of
1g containing polymyxin E 2mg, tobramycin 1.8mg and ampho-
tericin B 10 mg (PTA) or placebo lozenges. The ingredients of the
placebo lozenge were identical with the PTA lozenge except the
active drugs. The colour, taste and form of the PTA and placebo
lozenges were identical as well. Randomisation was performed by
the hospital pharmacist according to a computer-generated, ran-
domised allocation schedule. Patients, clinicians, dental hygienists
and microbiologists were blind for who was taking antibiotics. The
patients used a PTA or placebo lozenge four times daily starting
the first day of irradiation during the total radiation period.
Assessments
The study period included only the first 5 weeks of radiation
because of the wide range of field changes above 50Gy of radiation.
During the study period mucositis, feeding and body weight scores
were performed at the start of radiotherapy and twice weekly
(Monday–Thursday). The assessments were performed by an
assigned dental hygienist. For each patient a mean weekly score
was calculated on the basis of these two scores. These mean scores
were used for further statistical analyses.
Twice weekly (Monday–Thursday) and two times before
the start of radiation oral washings were obtained to examine
the oral flora for Gram-negative bacilli, Candida species, viridans
streptococci, Enterococci, Staphylococcus aureus and coagulase-
negative Staphylococci.
Mucositis The mean mucositis was scored by using qualitative
and quantitative parameters (Spijkervet et al, 1989b). Four
different local signs of mucositis (k) might be distinguished:
1¼white discoloration; 2¼erythema; 3¼formation of pseudo-
membranes; 4¼ulceration. Mucositis of the oral cavity was
determined for maximally eight distinguishable irradiated areas
of the mouth: buccal mucosa (left and right), soft and hard palates,
dorsum and border of the tongue (left and right), and the floor of
the mouth. The degree of mucositis of each area was scored
according to the local signs of mucositis. The length (E) of the local
sign of mucositis was measured: 1¼p1cm; 2¼1–2cm; 3¼2–
4cm; 4¼X4cm. The degree of mucositis was defined as the
product of the values k and E. The mucositis score was defined as
the mean of the scores assigned to the irradiated areas.
The mucositis was also scored according to the WHO score
(grade 0¼normal, no mucositis; grade 1¼soreness and erythema;
grade 2¼erythema, ulcers, can eat solids; grade 3¼ulcers, requires
liquid diet only; grade 4¼alimentation not possible) (Anonymous,
1979).
Feeding The quality of feeding was scored (0¼normal, no changes;
1¼symptoms without medication; 2¼symptoms with medication;
3¼liquid diet only; 4¼nasogastric tube feeding) and body weight
was determined. Afterwards the changes in weight were scored.
Microbiological methods To acquire an oral washing, patients
gargled and rinsed their mouth with 10ml sterile saline for 30s,
and spit it into a sterile vial.
One millilitre of the sample was diluted in 9ml of Brain Heart
infusion (BHI) (Oxoid, Basingstoke, England) and this suspension
was serially diluted in BHI. The suspensions were than plated out
onto 5% sheep blood agar, McConkey-3 agar (Oxoid) and Yeast
morphology agar (Merck, Darmstadt, Germany). The agar plates
and BHI broth cultures tubes were incubated overnight aerobically
at 371C. If an agar plate did not show growth and the
corresponding BHI broth culture of the dilution series did show
turbidity, then this suspension was plated again onto the agars
mentioned above. With this enrichment step even low numbers of
Candida species and Gram-negative bacilli could be detected
(Spijkervet et al, 1989a). By reading and counting the plates after
incubation the viable numbers of microorganisms per millilitre
was estimated. The identification was performed by standard
microbiological techniques.
Definitions Carriage of a particular microorganism was defined
as the condition in which a patient showed a minimum of two
consecutive oral washings positive for that organism.
Colonisation index of the oral cavity was defined as the sum of
logarithms of the concentrations of a particular microorganism
isolated from 1ml of oral-washing specimens divided by the
number of oral washings.
Statistical analysis
Sample size calculation of this study was based on the study by
Spijkervet (Spijkervet et al, 1990). A two-sided a of 5% and a
power of 80% were used. Additionally, a 50% reduction of
mucositis in the PTA group was determined as clinically relevant
with a normal incidence of mucositis of 80%. Based on these
assumptions, 27 patients in each group would be sufficient.
Intention-to-treat analysis was performed. The difference of drop-
outs between both groups was analysed using Fisher’s exact test.
The results were analysed, with respect to mean mucositis, the
loss of weight, and colonisation numbers for five different
microorganisms (t-test for independent samples) and the WHO
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lmucositis score and feeding (Mann–Whitney U test). Two-sided
tests, performed at the 5% level of significance, were used.
RESULTS
Patient characteristics are shown in Table 1. From January 1994 to
February 1997, 65 patients were included, 33 patients received PTA
lozenges and 32 the placebo lozenges. Out of the 65 included
patients, 58 patients were evaluable for the total evaluation period
of 5 weeks. Seven patients (11%) dropped out earlier from the
study, five of the PTA group (15%) and two of the placebo group
(6%). The difference of dropouts between both groups was not
significant. One patient (PTA) developed a skin reaction, unlikely
caused by the PTA lozenges, and one patient (placebo) could not
suck the lozenges because of the tumour surgery of his tongue. The
other five dropped out for reasons not related to one of the
lozenges. Of the seven dropouts, one patient stopped after 1 week,
two patients after 2 weeks, one patient after 3 weeks and three
patients after 4 weeks radiation.
Mucositis
The mean mucositis was the same in the PTA group and the
placebo group during the study period (P40.2) (Figure 1). During
the 5-week observation period 89% of the patients in the PTA
group developed pseudomembranes and in the placebo group
94%. The mucositis according to the WHO score did not differ
throughout the study period between both groups (P40.5). In the
PTA group, 80% of the patients developed grades 3 and 4
mucositis according to the WHO score, and in the placebo group
90%. The appearance of pseudomembranes was for both groups at
a similar radiation status; after 30Gy of radiation.
Feeding
Six patients (19%) in the placebo group (n¼32) and two patients
(6%) in the PTA group (n¼33) needed nasogastric tube feeding
during the evaluation period (P¼0.08).
Body weight
The mean weight loss after 5 weeks of radiation was less in the PTA
group by 1.3kg (s.d. 3.0) than in the placebo group 2.8kg (s.d. 2.9)
(P¼0.05).
Microorganisms
For viridans streptococci, Enterococci, Staphylococcus aureus and
coagulase-negative Staphylococci, a similar pattern of carriage and
colonisation was found in both groups.
The colonisation and carriage of Candida species at baseline was
equal in both groups (P40.8). During the first two radiation weeks
the colonisation for Candida species showed an increase in the
placebo group and a decrease in the PTA group. After 2 weeks, an
increase in both groups was found but the difference between the
two groups remained significant during the total study period
(Po0.05) (Figure 2).
During the first 4 weeks a significant difference was found for
the carriage of Candida species (Po0.03).
Table 1 Patient characteristics
Patients characteristics Placebo PTA P-value
aAge mean7sd (years) 54 (10.8) 56 (12.5) 0.36
Gender: male/female (n) 22/10 24/9 0.79
Tumor site
Oral cavity (n) 17 23 0.41
Oropharynx (n)1 0 8
Hypopharynx (n)1 1
Unknown primary(n)4 1
Histology
Squamous (n) 31 32 1.0
Other (n)1 1
T-stage
T1 (n) 4 5 0.25
T2 (n)6 5
T3 (n)8 8
T4 (n)9 1 4
bTx (n)5 1
N-stage
N0 (n) 10 14 0.12
N1 (n)6 1 0
N2a (n)2 1
N2b (n)9 3
N2c (n)1 3
N3 (n)4 2
Surgery
Yes (n) 21 27 0.17
No (n)1 1 6
Dentures
Yes (n) 20 25 0.29
No (n)1 2 8
All differences between the groups were analysed using w
2 test except
ain which
t-test was used.
bSix patients with an unknown primary tumour.
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Figure 1 The mean mucositis score (7s.d.) for the PTA group (n) and
the placebo group (&).
Figure 2 Percentage of patients colonised for Candida species for the
PTA group (lines) and the placebo group (solid).
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lThe colonisation and carriage of aerobic Gram-negative bacilli
at baseline was equal in both groups (P¼0.9). During the radiation
period the colonisation in the PTA group was less than in the
placebo group, but the difference was only significant in the
second week of radiation (P¼0.05) (Figure 3).
During the first 2 weeks the carriage of aerobic Gram-negative
bacilli was reduced in the PTA group (Po0.04). In weeks 3–5 the
difference was no longer significant.
All results are summarised in Table 2.
DISCUSSION
In this study, no effect of selective oral flora elimination on
mucositis was observed. The development of mucositis follows the
same pattern as reported in an earlier cohort study (Spijkervet et al,
1989c). According to the WHO score, 80% of the patients in the
PTA group and 90% in the placebo group developed mucositis
grades 3 and 4. This severity of mucositis is in accordance with the
outcomes of Okuno et al (1997). In other studies, different
outcomes are reported. A significant reduction of mucositis in the
PTA group was found by two groups (Spijkervet et al, 1990;
Kaanders et al, 1995). Both studies are nonrandomised clinical
trials and the PTA group is compared with a historical control
group.
A reduction in mucositis distribution and affected area,
dysphagia and weight loss in the PTA group is reported by
Symonds et al. (1996). From a total of 221 patients in that study, 98
(44%) patients had a larynx carcinoma (PTA¼57, placebo¼41).
Of these patients, the radiation field included only a minor part of
the oral mucosa, in which mucositis could develop. In the study
of Okuno et al only a subjective patient-reported amelioration of
mucositis was reported but no reduction was found in clinically
observed mucositis (Okuno et al, 1997). The PTA group (n¼54) in
that study consisted of an unblinded (n¼29) and a blinded
(n¼26) group. Only in the unblinded PTA group the mean
mucositis, reported by the patients was lower than the placebo
group. Recently, it was shown in a randomised study including 77
patients that selective oral flora elimination does not reduce
radiation mucositis (Wijers et al, 2001). A problem in that study is
the short evaluation time of only the first 3 weeks of radiotherapy.
Whereas normally development of severe mucositis starts after 3
weeks of radiation (Kaanders et al, 1999).
A complicating factor in comparing outcomes from different
studies is the assessment method of mucositis. All studies used
different scoring methods. Therefore, two scoring methods were
used in the current study. The WHO score is a widely accepted
method, but this score is a combination of local mucositis signs
and general complaints (Anonymous, 1979). The other scoring
method in the current study is based only on mucosal signs of
mucositis (Spijkervet et al, 1989b). It therefore provides a more
precise estimation of the mucositis development at the mucosal
level. It further makes a comparison possible with outcomes of
Figure 3 Percentage of patients colonised for aerobic Gram-negative
bacilli for the PTA group (lines) and the placebo group (solid).
Table 2 Results of the PTA–placebo group for mean mucositis, weight loss, carriage and colonisation index of Candida species and aerobic Gram-
negative bacilli
01234 5
Week X s.d. X s.d. X s.d. X s.d. X s.d. X s.d.
Mean mucositis
PTA 0 0 0.5 0.7 2.2 1.7 4.6 2.7 4.5 2.7 5.0 2.3
Placebo 0 0 0.3 0.4 2.6 2.0 4.8 2.3 4.9 2.5 5.2 2.8
Weight loss
PTA 0 0  0.3 1.0 0.4 1.3 0.6 2.1 1.0 2.7 1.3 3.0
Placebo 0 0 0.3 0.9
a 0.6 1.2 1.3 1.7 2.2 2.3 2.8 2.9
a
Candida col. Index
PTA 1.0 1.3 0.4 0.8 0.5 0.9 0.6 0.9 0.8 1.5 1.0 1.5
Placebo 1.1 1.3 1.2 1.6
a 1.6 1.7
a 1.7 1.7
a 2.0 1.7
a 1.9 1.8
a
Candida carriage
PTA (%) 48 23.5 17.6 31.8 30.8 36
Placebo (%) 52 76.5
b 82.4
b 68.2
b 69.2
b 64
Aerobic Gram-negative bac. col. Index
PTA 0.7 1.2 0.4 0.8 0.4 0.9 0.6 1.2 0.5 1.0 0.4 0.9
Placebo 0.7 1.4 0.8 1.1 0.9 1.1
a 0.8 1.0 0.8 1.4 0.8 1.5
Aerobic Gram-negative bac. Carriage
PTA (%) 52.4 23.1 25 42.9 54.5 40
Placebo (%) 47.6 76.9
b 75
b 57.1 45.5 60
aRepresents a significant difference between the PTA and placebo group using an independent sample t-test.
bRepresents a significant difference between the PTA and placebo
group using w
2 test.
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learlier publications (Spijkervet et al, 1989b; Parulekar et al, 1998).
For future studies, we recommend the use of the OMAS-score from
the mucositis study group because this scoring method is a
reliable, well-validated and widely accepted method (Sonis et al,
1999). This scoring method was published later than the start of
the current study and was therefore not used as a scoring method
in this study.
In the current study, patients who received PTA lozenges
had less weight loss than patients receiving placebo lozenges,
assuming a better feeding status of the PTA-group patients (mean
difference 1.5kg). Owing to the minimal effect of PTA on the
mucositis level, we found the feeding outcome of minor clinical
relevance.
In our study, carriage and colonisation of aerobic Gram-
negative bacilli and Candida species decreased in the PTA group
but was not totally eradicated. These findings are in line with the
findings of other studies (Spijkervet et al, 1990; Kaanders et al,
1995; Symonds et al, 1996; Wijers et al, 2001). Based on these
findings and the development and severity of mucositis it can be
concluded that the presence of Candida species and aerobic Gram-
negative bacilli has no influence on the development of radiation-
induced mucositis. The increase of the carriage and colonisation of
Candida species and aerobic Gram-negative bacilli after 3 weeks of
radiation may be explained by the development of xerostomia,
which makes dissolving of the lozenges more difficult. Wijers et al
tried to overcome this problem by using a paste instead of a
lozenge. However, the paste appeared to be an unsuccessful form
of application because already after randomisation 32% of the
patients refused further participation and 77% of the patients
dropped out after four study weeks because of bad taste and
unpleasant sensation of the paste texture in the mouth (Wijers et al,
2001).
In conclusion, PTA lozenges have a positive effect on the quality
of feeding and the amount of weight loss but cannot prevent severe
mucositis. The presence of Candida species and aerobic Gram-
negative bacilli has no effect on the development and severity of
radiation-induced mucositis. Based on our findings of this
randomised clinical trial, we do not recommend this type of
supportive care for the reduction or prevention of radiation
mucositis.
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